Use of convalescent plasma for COVID-19 in India: A review & practical guidelines.
Indian J Med Res
; 153(1 & 2): 64-85, 2021.
Article
in En
| MEDLINE
| ID: mdl-33818467
ABSTRACT
Convalescent plasma (CP) therapy is one of the promising therapies being tried for COVID-19 patients. This passive immunity mode involves separating preformed antibodies against SARS-CoV-2 from a recently recovered COVID-19 patient and infusing it into a patient with active disease or an exposed individual for prophylaxis. Its advantages include ease of production, rapid deployment, specificity against the target infectious agent, and scalability. In the current pandemic, it has been used on a large scale across the globe and also in India. However, unequivocal proof of efficacy and effectiveness in COVID-19 is still not available. Various CP therapy parameters such as donor selection, antibody quantification, timing of use, and dosing need to be considered before its use. The current review attempts to summarize the available evidence and provide recommendations for setting up CP protocols in clinical and research settings.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Guideline
Limits:
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
Indian J Med Res
Year:
2021
Document type:
Article
Affiliation country:
India